BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pegargiminase readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Pegargiminase\, from ClinicalTrials.gov e
 stimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05001828-2830@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Pegargiminase: Phase 1 readout est. (NCT05001828)
DESCRIPTION:Pegargiminase\, phase 1\, Acute Myeloid Leukemia.\nStudy: Study
  of ADI-PEG 20\, Venetoclax and Azacitidine in Acute Myeloid Leukemia\nEst
 imated primary completion: January 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/pegargiminase#upcoming-events\nRegistry record: https:
 //clinicaltrials.gov/study/NCT05001828
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04587830-2830@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Pegargiminase: Phase 2 readout est. (NCT04587830)
DESCRIPTION:Pegargiminase\, phase 2.\nStudy: ADI-PEG 20 Plus Radiotherapy a
 nd Temozolomide in Subjects With Glioblastoma Multiforme\nEstimated primar
 y completion: 28 February 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/pegargiminase#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT04587830
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06085729-2830@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20270902
DTEND;VALUE=DATE:20270903
SUMMARY:Pegargiminase: Phase 1/2 readout est. (NCT06085729)
DESCRIPTION:Pegargiminase\, phase 1/2.\nStudy: Phase I/II Study of PEGylate
 d Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men W
 ith Aggressive Variant Prostate Cancers (AVPC)\nEstimated primary completi
 on: 2 September 2027. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /pegargiminase#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT06085729
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05842512-2830@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Pegargiminase: Phase 2 readout est. (NCT05842512)
DESCRIPTION:Pegargiminase\, phase 2.\nStudy: Study of ADI-PEG 20 Versus Pla
 cebo in Subjects With NASH\nEstimated primary completion: 31 December 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/pegargiminase#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05842512
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03970447-2830@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Pegargiminase: Phase 2/3 readout est. (NCT03970447)
DESCRIPTION:Pegargiminase\, phase 2/3.\nStudy: A Trial to Evaluate Multiple
  Regimens in Newly Diagnosed and Recurrent Glioblastoma\nEstimated primary
  completion: June 2028. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/pegargiminase#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT03970447
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05317819-2830@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20280930
DTEND;VALUE=DATE:20281001
SUMMARY:Pegargiminase: Phase 3 readout est. (NCT05317819)
DESCRIPTION:Pegargiminase\, phase 3\, Hepatocellular Carcinoma.\nStudy: Stu
 dy of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and U
 nresectable Hepatocellular Carcinoma\nEstimated primary completion: Septem
 ber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout 
 date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegargimina
 se#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0
 5317819
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07389278-2830@assetmemo.bio
DTSTAMP:20261121T005820Z
DTSTART;VALUE=DATE:20320630
DTEND;VALUE=DATE:20320701
SUMMARY:Pegargiminase: Phase 1/2 readout est. (NCT07389278)
DESCRIPTION:Pegargiminase\, phase 1/2.\nStudy: Combination ADI-PEG 20\, TMZ
 \, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG)\nEstima
 ted primary completion: 30 June 2032. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/pegargiminase#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT07389278
URL:https://assetmemo.bio/drug/pegargiminase#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
